Table 1. Patient characteristics.
| Patient number |
Age | ISS | Sex | High risk cytogenetics | Induction | Conso-lidation | Response post ASCT or consolidation | Pre LEN timepoint (weeks after ASCT) |
Start LEN maintenance (weeks after ASCT) |
LEN Timepoint (weeks after ASCT) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63,2 | 2 | F | NO | VD × 4 | NO | sCR | 25,9 | 28,0 | 62,0 |
| 2 | 59,2 | 1 | F | NO | vtD × 4 | NO | VGPR | 22,4 | 25,6 | 54,6 |
| 3 | 63,0 | 1 | F | NO | vtD × 4 | NO | VGPR | 35,4 | 38,1 | 48,6 |
| 4 | 51,7 | 2 | F | YES (gain 1q) | VD × 4 | NO | VGPR | 16,4 | 17,6 | 29,6 |
| 5 | 60,0 | 2 | F | NO | VD × 4 | NO | sCR | 18,9 | 24,0 | 41,0 |
| 6 | 63,6 | 2 | M | YES (t(4;14) and del(17p)) | vtD × 4 | NO | VGPR | 15,9 | 29,0 | 47,0 |
| 7 | 62,7 | 1 | M | NA | vtD × 4 | NO | sCR | 15,9 | 20,7 | 41,0 |
| 8 | 64,7 | 3 | M | NA | vtD × 4 | vtD × 2 | VGPR | 23,9 | 26,9 | 57,3 |
| 9 | 66,0 | 3 | M | NO | vtD × 4 | vtD×2 | CR | 25,9 | 29,6 | 59,0 |
| 10 | 61,9 | 3 | F | NA | vtD × 4 | NO | VGPR | 13,1 | 17,1 | 39,9 |
| 11 | 52,0 | 3 | M | NO | vtD × 4 | vtD x 2 | VGPR | 12,9 | 25,0 | 46,0 |
| 12 | 58,1 | 2 | M | NO | vtD × 4 | vtD x 2 | VGPR | 23,1 | 26,0 | 41,3 |
| 13 | 53,7 | 3 | F | NA | vtD × 4 | NO | CR | 14,1 | 16,3 | 24,3 |
| 14 | 59,1 | 1 | F | NO | VD × 5 | NO | VGPR | 15,4 | 27,1 | 64,6 |
| 15 | 58,4 | 2 | M | NO | vtD × 4 | NO | sCR | 21,9 | 29,7 | 40,0 |
| 16 | 55,9 | 2 | F | NO | vtD × 4 | NO | sCR | 18,1 | 21,3 | 35,3 |
| 17 | 51,9 | 1 | M | NO | vtD × 4 | NO | VGPR | 17,1 | 25,0 | 39,3 |
VD: Bortezomib - Dexamethasone. vtD: Bortezomib-Thalidomide-Dexamethasone. VGPR: Very good partial response. CR: complete response. sCR: stringent complete response. NA: not available. ISS: international staging system. M: Male, F: Female.